Top stories

View all news

Gavi, the Vaccine Alliance, welcomes the announcement by the United States Government of its strategy for global vaccine sharing, which sets out how it will provide at least 80 million doses of vaccines to the rest of the world – with the…

The Gavi COVAX AMC Summit “One World Protected” virtual event, hosted today by the Government of Japan and Gavi, the Vaccine Alliance, raised US$ 2.4 billion from nearly 40 donor governments, the private sector and foundations, exceeding the…

Responding to an urgent need for doses around the world, the Government of New Zealand has pledged to transfer 1.6 million doses allocated through COVAX to lower-income economies.

COVAX vaccine roll-out

>80 million COVAX vaccines shipped
OWP
129 participants

As of 4 June 2021

COVAX Facility

Gavi is co-leading COVAX, the vaccines pillar of the Access to COVID-19 Tools (ACT) Accelerator. This involves coordinating the COVAX Facility, a global risk-sharing mechanism for pooled procurement and equitable distribution of COVID-19 vaccines.

Learn more

The COVID-19 vaccine race

Pre-clinical
184vaccines
are being explored in lab experiments and animals
PHASE 1
35 vaccines
are undergoing safety tests in healthy young individuals
Phase 2
36vaccines
are being tested in broader groups of people
Phase 3
25vaccines
are in large international trials to test their impact on COVID-19
IN USE
15vaccines
are currently being offered to the general population
Phase 4
5vaccines
are being monitored in the wider population after being approved

Source: WHO

Learn more

COVID-19 vaccines

Accurate, evidence-based information about COVID-19 vaccines to provide people with essential facts about the vaccines that will help end this crisis.

Learn more

Accurate, evidence-based information about COVID-19 vaccines to provide people with essential facts about the vaccines that will help end this crisis.

Learn more

#VaccinesWork

Vaccines are one of the most successful and cost-effective health investments in history with wider benefits that accrue across a lifetime.

Keep informed about the latest topics in global health, including top stories related to the ongoing coronavirus (COVID-19) outbreak.

Learn more

Vaccines are one of the most successful and cost-effective health investments in history with wider benefits that accrue across a lifetime.

Keep informed about the latest topics in global health, including top stories related to the ongoing coronavirus (COVID-19) outbreak.

Learn more

Top VaccinesWork stories

View all stories

The death toll from the pandemic has been devastatingly high, with the official figure standing at 3.5 million people, but the World Health Organization estimates the real number could be up to three times higher. Here’s why.

A significant number of post-covid patients suffer from syndromes that few doctors understand.

Community health workers, government and aid agencies join a chorus of voices encouraging vaccinations in the DRC.

Supported countries

Supported Countries

Our impact

Syringe >822 million children immunised
First aid locator >14 million future deaths prevented
Transitioned 16 countries transitioned from Gavi support
Billions >150 US$ billion in economic benefits for countries (2000–2017)
Children 85% of the world's children reached by routine immunisation

Our mission: protect people's health

Saving children’s lives and protecting people’s health by increasing equitable use of vaccines in lower-income countries

Learn more

Saving children’s lives and protecting people’s health by increasing equitable use of vaccines in lower-income countries

Learn more

Our partners

Gavi draws on the skills of a variety of partners, combining the technical expertise of the development community with the business know-how of the private sector.

Meet the Vaccine Alliance partners

Gavi draws on the skills of a variety of partners, combining the technical expertise of the development community with the business know-how of the private sector.

Meet the Vaccine Alliance partners

Like. Follow. Share.

    Subscribe to our newsletter